In the first half of 2020, 68 listed pharmaceutical companies with revenues of more than 100 million yuan changed executives.

Pharmaceutical Network Market Analysis: According to incomplete statistics in the industry, since the first half of 2020, about 68 listed pharmaceutical companies with revenue of more than 100 million yuan have experienced personnel earthquakes, including China Pharmaceuticals, Fosun Pharma, Renfu Pharmaceuticals, Haizheng Pharmaceuticals, Ha Pharmaceuticals, China Resources Shuanghe and other well-known pharmaceutical companiesThe reasons for resignation mainly include work reasons, personal reasons, term of office, division of work adjustment, etc, which mainly for personal reasonsAmong them, Fosun Pharma's executive changes are more frequent, in the first half of the year has been five executives have left in successionThe four vice-presidents of Northeast Pharmaceuticals also have short termsfor this year's pharmaceutical executive changes more frequent reasons, industry analysis believes that there are two main aspects: the policy environment and market environment changesIn terms of the policy environment, in recent years, in the belt procurement, two-vote system, tender price reduction, medical insurance control fees and consistency evaluation and a series of medical reform policies, the pressure on pharmaceutical companies is relatively largeIn terms of market environment changes, the pharmaceutical market pattern is changing, competition has become more and more intenseunder the dual influence of policy and market, pharmaceutical companies still need to surviveThe industry pointed out that if pharmaceutical companies can not adapt to the new policy and market environment, still continue to use their original thinking and management methods, then once the performance is not completed, the frequent departure of senior executives will be easy to occurIt should be noted that in the period of change, the decision-making ability of pharmaceutical executives, the ability to recognize the market and policy, to a certain extent, determines the survival of pharmaceutical companies, it is also easy for executives to leave when they are unable to meet the needs of pharmaceutical companies, or when pharmaceutical companies are unable to provide the pay and career opportunities that executives expectthe first half of this year to leave the 68 listed pharmaceutical companies, mostly chemical pharmaceutical enterprises, Chinese medicine enterprises are relatively fewIndustry analysts believe that this is mainly based on this year, Chinese medicine has been re-recognized and concerned, many Chinese medicine enterprises are good performanceand carry out the implementation of the procurement policy, directly affect the performance of pharmaceutical enterprises, leading to the occurrence of personnel earthquakes As can be seen, these enterprises leave in addition to the senior management, there are a large number of middle and grass-roots pharmaceutical companies frequent changes, including active departure, but also passive layoffs drug-belt procurement is a reformed policy in the pharmaceutical industry that talks about lower drug prices by consolidating purchases At present, the third batch of volume procurement is also within reach With the normalization of collection, pharmaceutical companies in order to retain market share, they have to follow the trend of profits, to maintain a low price level In this process, the direct strategy is to reduce sales costs, change the past pharmaceutical representatives to promote marketing tactics, which is also easy to cause organizational structure adjustment in fact, as the impact of volume procurement continues to expand, not only domestic pharmaceutical companies, international giants are also working to adjust the structure, such as Pfizer in the recent removal of the position of chief operating officer, Novartis core products "good" national sales and market access strategy head position cancellation industry analysts believe that in the era of drug profits, the future may occur three major changes, one is the trend of reduced staffing of pharmaceutical representatives; overall, executive changes in pharmaceutical companies are likely to continue in the second half of the year With the third batch of tape procurement approaching, pharmaceutical companies need to quickly adjust the cost structure in a new wave of price reduction, optimize marketing efficiency, in order to grasp market opportunities While the pharmaceutical industry has a promising future as a new demand, the challenges facing pharmaceutical companies are also serious.